Skip to Main Content

Patient Education Day - SNMMI 2016

NorCal CarciNET Community is once again working with the Society of Nuclear Medicine and Molecular Imaging (SNMMI) to host a free Patient Education Day during the Society's annual meeting in San Diego on June 12th, 2016. This day long patient centered program is will cover the history and safety and future of nuclear medicine. There will also be a NET breakout, that will focus exclusively on Neuroendocrine Tumors, imaging and treatment. 

There is no charge for registration, which also includes access to all SNMMI sessions Saturday - Tuesday.  To view all NET related session click here and proceed to June's calendar.

Reg

 

Lutathera Expanded Access Program In U.S. Now Open

AAA Opens Lutathera Expanded Access Program In U.S. to Eligible Patients And Announces Forthcoming NDA Filing to FDA and EMA.

AAA today announced that the company has initiated an expanded access program (EAP) in the United States for the investigational product, Lutathera. Through the program, Lutathera is being made available for patients suffering from inoperable, somatostatin receptor positive, midgut carcinoid tumors, progressive under somatostatin analogue therapy. Healthcare professionals and patients can learn more about the Lutathera EAP by visiting www.clinicaltrials.gov (trial number: NCT02705313). To read more visit AAA's website.

2016 Bay Area Neuroendocrine Patient Conference - Hosted by UCSF

2016 Neuroendocrine Tumor Patient ConferenceUCSF Diller navy
Hosted by:UCSF Helen Diller Family Comprehensive Cancer Center
In cooperation with NorCal CarciNET Community, NET Research Foundation, Stanford University Medical Center

Sunday, January 24, 2016 - 9:00 am to 4:30 pm

View the recording of the LiveStream  

Read more …

SNMMI / NorCal CarciNET PRRT Webinar

On October 20, 2015 the Society for Nuclear Medicine and Molecular Imaging and the NorCal CarciNET Community hosted a webinar on PRRT featuring Dr. Ed Wolin and Dr. Eric Mittra. NorCal CarciNET's Josh Mailman facilitated the ensuing question and answer session. Over 95 participated in the webinar which can be viewed below. In addition the slides that were used are available by clicking here. Guidelines for the use of PRRT are avialble from the PRRTInfo.org website. 

You may use the share icon (looks like an airplane) to embed this video in another site.

Updates from ESMO

In addition to the NETTER1 trial presented at the European Cancer Congress, two other phase 3 NET clinical trials presented their results.

Everolimus conferred a statistically significant and clinically meaningful PFS benefit with an acceptable safety profile in patients with advanced, progressive neuroendocrine tumors of the lung or gastrointestinal region, according to phase 3 trial results (Radiant4). 

Read more …

  1. Results from first large scale PRRT trial released
  2. Two NET Abstracts Set for Presentation at Presidential Session of ECC 2015
  3. Lexicon Reports Positive Top-Line Results for Phase 3 Telotristat Etiprate Study
  4. NorCal CarciNET President awarded
  5. Patient Program at 3rd Theranostic World Congress
  6. Special Meeting Annoucement

Page 5 of 10

Copyright ©2025 ADG. All Rights Reserved | Web Design & Development by ADG Creative, a division of ADG. ADG is a certified Women Owned Business.